NCT01903928View on ClinicalTrials.gov

A Study to Evaluate Safety and Tolerability of a Therapeutic Vaccine, ASP0113, in Subjects Undergoing Allogeneic Hematopoietic Cell Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 20, 2013

Primary Completion Date

January 19, 2015

Study Completion Date

January 19, 2015

Conditions
Allogeneic Hematopoietic Cell Transplant
Interventions
BIOLOGICAL

ASP0113

injection

Trial Locations (2)

Unknown

Kantou

Kyushu

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY